SYNC-T demonstrated high efficacy in resolving bone metastases in metastatic prostate cancer, achieving an 87% overall response rate in a phase 1 trial. The therapy involves a minimally-invasive ...

MRI outperformed micro-ultrasound in sensitivity and negative predictive value for prostate cancer detection. Micro-ultrasound offers a short learning curve and real-time lesion identification, ...

Alicia Morgans, MD, MPH, and Paul Sieber, MD, introduce the discussion, outlining goals to connect evolving mCRPC research with personalized immunotherapy practice. The experts conclude with a forward ...

The approval is supported by results from the phase 3 KEYNOTE-905/EV-303 trial. On November 21, 2025, the FDA approved pembrolizumab (Keytruda) and pembrolizumab and berahyaluronidase alfa-pmph ...

Most NMIBC patients rely on healthcare providers for treatment decisions, but desire more comprehensive discussions about options. Patients prefer treatments beyond chemotherapy, with 81% interested ...

YOLT-203 is an investigational gene-editing therapy for PH1, aiming to reduce oxalate overproduction by deactivating glycolate oxidase. The pivotal trial will assess YOLT-203's safety and efficacy in ...

The subcutaneous formulation of pembrolizumab is approved for all adult indications in Europe, offering faster administration than the intravenous version. Phase 3 trial results showed noninferior ...

The ExactVu micro-ultrasound platform is noninferior to MRI in detecting clinically significant prostate cancer in biopsy-naïve men. Microultrasonography offers a cost-effective, in-office alternative ...

Fast track designation accelerates development of [68Ga]Ga-DPI-4452 for ccRCC detection, enhancing FDA engagement and review processes. ITM-94, a gallium-68-radiolabeled PET agent, forms a theranostic ...

An expert discusses how KEYNOTE-905 establishes a new evidence-based systemic therapy option that transforms the management and prognosis of patients with muscle-invasive bladder cancer. The ...